This study tests a simple idea: that pairing these ADCs with the right partner drugs could make them work better. The team is examining combinations involving Dato‑DXd for ovarian cancer, and T‑DXd for cancers of the oesophagus, stomach, and endometrium.
To understand and more effectively treat TP53 mutations that interfere with calcium signalling, a process which strengthens cancer cells.
Cancer treatment has changed dramatically in recent years, but the way doctors manage cancer‑related pain has barely budged. Much of that stagnation stems from a simple problem: scientists still do not fully understand how tumours and the nervous system interact.A new multidisciplinary effort hopes to change that. By bringing together specialists in cancer biology, neurobiology, pain research and calcium signalling, the project aims to illuminate how tumour cells and nerve cells influence one another—both during normal growth and under the assault of chemotherapy. The hope is that new laboratory models will reveal the hidden mechanisms that drive both pain and cancer progression.Armed with those insights, the team plans to test existing and experimental biologic drugs, alone and in combination, to see whether they can tackle tumour growth and cancer pain at the same time. The ambition is not merely to ease suffering, but to rethink how pain and cancer biology can be targeted together rather than treated as separate problems.
To elucidate mechanisms and mediators of crosstalk between cancer cells and neurons in both pathology and treatment paradigms, to identify novel biotherapeutic targets, and devise better strategies for the application and toleration of existing therapies that could improve patient outcomes.
For patients with glioblastoma, pancreatic or endometrial cancers, the hunt for effective treatments is often a race against biology. One promising avenue lies in the cell’s own repair machinery. Every cell relies on a DNA‑damage response system to fix routine wear and tear. When cancer disrupts part of that system, it creates an Achilles heel. Researchers are now exploiting this vulnerability through “synthetic lethality,” a strategy that targets the remaining repair pathways the tumour still depends on.By blocking those last‑ditch survival tools, the cancer cell is pushed past its limits, unable to recover from the damage it accumulates. Healthy cells, with intact repair systems, are largely spared. The hope is that these genetic weak spots can be turned into a guidebook for new therapies—precise combinations that strike tumours where they are most fragile and offer patients with the toughest cancers a better chance.
Mutations that dysregulate the DNA damage response (DDR) are often pivotal in determining whether a cancer cell survives or succumbs to treatment. By identifying novel combinatorial therapies that exploit these vulnerabilities through synthetic lethality, we can develop more effective strategies for treating refractory cancers and significantly improve patient outcomes.